CREDENCE Trial
In the prospective, multicenter CREDENCE trial, Cleerly ISCHEMIA demonstrated higher diagnostic accuracy and area under the curve compared to FFRCT and stress testing, as referenced to 868 invasive measurements by fractional flow reserve (FFR), the ‘gold standard’ for determining ischemia.2
PACIFIC Trial
In a post-hoc analysis of the PACIFIC study, Cleerly ISCHEMIA was compared to FFRCT, 15O-H2O PET and SPECT to predict invasive FFR≤0.8 as reference standard. On a per-patient basis Cleerly ISCHEMIA, FFRCT and PET performed similarly and outperformed SPECT in predicting ischemia.2 Cleerly ISCHEMIA, using multivariate analysis, was the only non-invasive ischemia test that was prognostic of future MACE events, FFRCT and SPECT were not.2
